Corporate Profile
Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM).
* Note: In September 2006, Cardiome announced that RSD1235 has been assigned the name "vernakalant hydrochloride" by the United States Adopted Names (USAN) Council. References to RSD1235 (iv) are now vernakalant (iv), and references to RSD1235 (oral) are now vernakalant (oral).